Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ADC Therapeutics Q2 Adj. EPS $(0.25) Beats $(0.39) Estimate, Sales $18.839M Beat $17.776M Estimate

Author: Benzinga Newsdesk | August 12, 2025 06:31am
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.39) by 35.9 percent. This is unchanged from the same period last year. The company reported quarterly sales of $18.839 million which beat the analyst consensus estimate of $17.776 million by 5.98 percent. This is a 8.21 percent increase over sales of $17.410 million the same period last year.

Posted In: ADCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist